Cipher Pharmaceuticals

Cipher Pharmaceuticals is a specialty pharmaceutical company in Charleston, SC. It acquires products that fulfill unmet medical needs, manages the clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Cipher operates a lean corporate structure, employs strategic operational partnerships, out- and in-licenses products, and makes selective investments in drug development to assemble a portfolio of prescription products. Its team and board of directors bring decades of experience in developing and commercializing dermatology products.

Cipher's portfolio spans dermatology, hospital acute care, and out-licensed products. In dermatology, it offers Actikerall, a topical solution for hyperkeratotic actinic keratosis of the face, forehead, and balding scalp; Epuris, an oral retinoid for severe nodular and inflammatory acne in patients 12 and older; Vaniqa, a topical cream that slows the growth of unwanted facial hair in women; and Natroba, a topical suspension approved in the United States as a pediculicide for head lice in patients 6 months and older and a scabicide for scabies in patients 4 years and older. In hospital acute care, it offers Aggrastat, an intravenous anti-platelet drug for patients with Acute Coronary Syndrome, and Brinavess, for rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Through global partnerships, Cipher generates royalty revenue from four brands: Absorica, marketed in the United States with Sun Pharmaceuticals; ConZip, marketed with Vertical Pharmaceuticals; and Lipofen, marketed with Ani Pharmaceuticals.

Cipher's team and board have a record of success in developing and commercializing dermatology products as the company expands its product offerings and presence in North America. For patients and healthcare professionals, the company maintains medical information and adverse event reporting support.